Sarcomatoid lung carcinomas show high levels of programmed death ligand-1 (PD-L1)

Journal of Thoracic Oncology

Volumn 8, Issue 6, 2013, Pages 803-805

  Velcheti, Vamsidhar ^a   Rimm, David L ^a   Schalper, Kurt A ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Immunotherapy; Lung cancer; Programmed death receptor 1; Sarcomatoid carcinoma

Indexed keywords

PROGRAMMED DEATH 1 LIGAND 1;

ADULT; AGED; ARTICLE; CANCER IMMUNOTHERAPY; CLINICAL ARTICLE; COHORT ANALYSIS; EXTRACELLULAR SPACE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE; LUNG CARCINOMA; MALE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; SARCOMATOID CARCINOMA; TROPHOBLAST; TUMOR DIFFERENTIATION;

EID: 84879465848     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e318292be18     Document Type: Article

References (14)

1. Zou W, Chen L. Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol 2008;8:467-477. (Pubitemid 351733418)
2. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366:2443-2454.
3. Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti- PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012;366:2455-2465.
4. Beasley MB, Brambilla E, Travis WD. The 2004 World Health Organization classification of lung tumors. Semin Roentgenol 2005;40:90-97. (Pubitemid 40417889)
5. Fishback NF, Travis WD, Moran CA, Guinee DG Jr, McCarthy WF, Koss MN. Pleomorphic (spindle/giant cell) carcinoma of the lung. A clinicopathologic correlation of 78 cases. Cancer 1994;73:2936-2945. (Pubitemid 24170766)
6. Anagnostou VK, Syrigos KN, Bepler G, Homer RJ, Rimm DL. Thyroid transcription factor 1 is an independent prognostic factor for patients with stage I lung adenocarcinoma. J Clin Oncol 2009;27:271-278.
7. Anagnostou VK, Dimou AT, Botsis T, et al. Molecular classification of nonsmall cell lung cancer using a 4-protein quantitative assay. Cancer 2012;118:1607-1618.
8. McCabe A, Dolled-Filhart M, Camp RL, Rimm DL. Automated quantitative analysis (AQUA) of in situ protein expression, antibody concentration, and prognosis. J Natl Cancer Inst 2005;97:1808-1815. (Pubitemid 43033901)
9. Camp RL, Chung GG, Rimm DL. Automated subcellular localization and quantification of protein expression in tissue microarrays. Nat Med 2002;8:1323-1327. (Pubitemid 35373567)
10. Venissac N, Pop D, Lassalle S, Berthier F, Hofman P, Mouroux J. Sarcomatoid lung cancer (spindle/giant cells): an aggressive disease? J Thorac Cardiovasc Surg 2007;134:619-623. (Pubitemid 47302002)
11. Ishida T, Tateishi M, Kaneko S, et al. Carcinosarcoma and spindle cell carcinoma of the lung. Clinicopathologic and immunohistochemical studies. J Thorac Cardiovasc Surg 1990;100:844-852.
12. Vieira T, Cazes A, Pierre B, et al. Is conventional chemotherapy effective in advanced sarcomatoid lung cancers? ASCO Meeting Abstracts 2012 30:e18102
13. Konishi J, Yamazaki K, Azuma M, Kinoshita I, Dosaka-Akita H, Nishimura M. B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression. Clin Cancer Res 2004;10:5094-5100. (Pubitemid 39106851)
14. Mu CY, Huang JA, Chen Y, Chen C, Zhang XG. High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation. Med Oncol 2011;28:682-688.